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Abstract: Exosomes are cell-derived nanovesicles that hold promise as living vehicles for 
intracellular delivery of therapeutics to mammalian cells. This potential, however, is undermined 
by the lack of effective methods to load exosomes with therapeutic proteins and to facilitate 
their uptake by target cells. Here, we demonstrate how a vesicular stomatitis virus glycopro-
tein (VSVG) can both load protein cargo onto exosomes and increase their delivery ability 
via a pseudotyping mechanism. By fusing a set of fluorescent and luminescent reporters with 
VSVG, we show the successful targeting and incorporation of VSVG fusions into exosomes 
by gene transfection and fluorescence tracking. We subsequently validate our system by live 
cell imaging of VSVG and its participation in endosomes/exosomes that are ultimately released 
from transfected HEK293 cells. We show that VSVG pseudotyping of exosomes does not 
affect the size or distributions of the exosomes, and both the full-length VSVG and the VSVG 
without the ectodomain are shown to integrate into the exosomal membrane, suggesting that 
the ectodomain is not required for protein loading. Finally, exosomes pseudotyped with full-
length VSVG are internalized by multiple-recipient cell types to a greater degree compared 
to exosomes loaded with VSVG without the ectodomain, confirming a role of the ectodomain 
in cell tropism. In summary, our work introduces a new genetically encoded pseudotyping 
platform to load and enhance the intracellular delivery of therapeutic proteins via exosome-
based vehicles to target cells.
Keywords: exosome, VSVG, protein delivery, nanotechnology
Introduction
Protein therapeutics are the fastest-growing class of US Food and Drug Administration 
(FDA)-approved drugs to treat the most difficult-to-manage human diseases, such as 
cancer, diabetes, and cardiovascular and neurologic disorders.1,2 However, the current 
regimen is mainly restricted to extracellular targets, due to the inability of proteins to 
enter cells. Exosomes, natural nanovesicles circulating in the human body, possess 
intrinsic ability to deliver various protein cargoes into recipient cells, thus representing 
an untapped source of effective delivery carrier toward intracellular targets. The 
concept of using exosomes for protein delivery has been attempted, but remains to 
be fully exploited.3–6
Exosomes are lipid bilayer-enclosed extracellular vesicles that transport proteins, 
nucleic acids, and lipids between cells.7–9 In mammals, exosomes are actively released 
by almost all types of cells, exist in body fluids, and circulate in the blood.10–12 Exosomes 
are recognized and endocytosed by tissue cells via specific interactions between surface-
membrane proteins, where after they deliver their molecular cargo.13–15 Therefore, 
they function in cell–cell communication and play important roles in immunodefense, 
pathogen spread, inflammation, tumor metastasis, and tissue repair.11,16–24 Exosomes 
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are designed by nature to deliver a large and specific cargo of 
functional biomolecules, a feature that is guiding the devel-
opment of exosome-based vehicles for targeted delivery of 
therapeutic agents.25–27 These studies, however, are impacted 
by gaps in our knowledge of exosome biogenesis and in 
approaches to engineer exosomes with a molecular cargo 
that enhances their uptake by target cells.
In this study, we describe a pseudotyping approach to load 
exosomal membranes with reporter and targeting proteins. 
Pseudotyping is often used in the production of recombinant 
viruses and involves packaging the genetic components of the 
virus (DNA or RNA) with envelope proteins derived from 
a different virus.28–30 This method allows one to select viral 
envelope proteins to alter host tropism, which may result 
in enhanced infection of the recombinant virus.31,32 The G 
glycoprotein of the vesicular stomatitis virus glycoprotein 
(VSVG) is frequently used for viral pseudotyping, owing to 
its broad tropism and high efficacy in transduction, and in 
fact most of the retroviruses approved for clinical trials are 
pseudotyped with VSVG.33–35 Mechanistically, VSVG is 
incorporated into the viral envelope during the budding of 
microdomains at the plasma membrane, the same domains 
involved in the formation of endosomes and exosomes.36 
This connection led us to propose the possibility of engi-
neering exosomes with specific membrane-bound proteins 
by expressing gene-encoding VSVG fusion proteins in their 
mother cells. Taking advantage of the modular structure and 
well-defined membrane topology of VSVG, we engineered 
VSVG to achieve the following two biological objectives: 
1) effective protein loading via terminal tagging of VSVG 
and 2) enhanced exosome uptake via VSVG pseudotyping. 
By generating exosomes that harbor a VSVG fusion with a 
protein that recognizes a surface biomarker on a target cell, 
it should be possible to generate exosomes repurposed as 
vehicles for intracellular delivery of functional fluorescent 
proteins and antibodies to diseased cells for high-contrast 
imaging and therapy, respectively.
Here, we report the first proof of concept of a pseudo-
typing approach to load exosomal membranes with a cargo 
of reporter proteins. We designed and constructed a set of 
VSVG fusion reporters and validated the ability of exosome 
incorporation in living human cells. These studies demon-
strated successful exosome targeting and protein loading via 
transfection and fluorescent monitoring in living mammalian 
cells. By domain swapping, we subsequently identified a 
minimal molecular scaffold of VSVG (mVSVG) that con-
tained sufficient signals for exosome targeting and protein 
loading. We further demonstrated robust internalization of 
pseudotyped exosomes by a variety of cell types, including 
four somatic and two induced pluripotent stem (iPS) cell 
lines. Collectively, our studies offer a simple and effective 
approach to engineer exosomes as vehicles for enhanced 
delivery of protein reporters and protein therapeutics to 
target cells.
Materials and methods
cell culture
Human embryonic kidney cells (HEK293) were purchased 
from Alstem (Richmond, CA, USA). Human glioblastoma 
cells (U87), human liver cancer cells (HEPG2), and mouse 
adipose tissue fibroblast cells (L929) were purchased from the 
American Type Culture Collection (Manassas, VA, USA). 
All cells were maintained in high-glucose Dulbecco’s Modi-
fied Eagle’s Medium supplemented with 10% fetal bovine 
serum, 2 mM GlutaMax (Thermo Fisher Scientific, Waltham, 
MA, USA), and 100 U/mL penicillin–streptomycin. 
At ~80%–90% confluence, cells were treated with 0.25% 
trypsin–ethylenediaminetetraacetic acid for dissociation 
and passed at a ratio of 1:4. Human iPS cells (iPS11 and 
iPS15) were purchased from Alstem. These lines have 
been preadapted to feeder-free conditions and maintained 
in serum-free mTeSR1 medium (Stemcell Technologies, 
Vancouver, BC, Canada) supplemented with 100 U/mL 
penicillin–streptomycin. All cells were incubated at 37°C 
in 5% CO
2
.
cell transfection
All transfections were performed in six-well plates unless 
otherwise stated. At ~60%–70% confluence, cells were 
transfected by plasmid DNA (1–2.5 µg/well) mixed with 
either Lipofectamine (Thermo Fisher Scientific) or FuGene 
6 transfection reagent (Promega, Fitchburg, WI, USA).
Design and construction of expression 
vectors for VsVg fusion proteins
Full-length VSVG (fVSVG) gene-encoding single- 
transmembrane protein was used for making various fusion 
constructs (Figure 1A and B). Fusion constructs were config-
ured 5′→3′ as per the following: a constitutive cytomegalo-
virus promoter, the signal peptide (SP), an in-frame insertion 
of red fluorescent protein (RFP) or Gaussia luciferase (Gluc), 
the stem sequence, transmembrane helix, the cytosolic tail, 
followed by an in-frame RFP, GFP, or Gluc lacking the 
endogenous SP sequences, and a stop codon (Figure 1B). 
A polyadenylation signal was added at the 3′ end. The 
construction of these fusion protein expression vectors was 
conducted using a combination of polymerase chain reac-
tion amplification for individual fragments and subsequently 
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seamless joining by enzymes from System Biosciences (Palo 
Alto, CA, USA).37 To display an RFP or Gluc on the outer 
surface of exosomes, the ectodomain of VSVG was swapped 
with indicated reporter proteins. To load RFP, GFP, or Gluc 
inside exosomes, these sequences were inserted at the end 
of the cytoplasm tail of VSVG (Figure 1B). Construction 
of both exosomes (CD63-GFP, CD81-GFP) and endo-
some markers (GFP-Rab5a) has been previously reported.5 
A positive exosome tracer, XPack-GFP, was purchased from 
System Biosciences. All final constructs were confirmed by 
double-stranded DNA sequencing (Elim Biopharmaceuticals, 
Hayward, CA, USA). Sequences of fVSVG and its fusion 
proteins were also provided (Supplementary materials).
Pseudotyping and preparation of 
exosomes
Pseudotyping and subsequent preparation of exosomes 
from culture cells were performed as described previously.5 
Briefly, HEK293 cells grown on 15 cm plates (70%–80% 
confluence) were transfected with FuGene transfection 
reagent. At 24 hours after transfection, cells were switched to 
serum-free UltraCulture medium (Lonza, Basel, Switzerland) 
for the production of pseudotyped exosomes. After 48 hours, 
the conditioned medium was collected and centrifuged at 
1,500 g for 5 minutes, then subjected to ultrafiltration with a 
0.22 µm filter. The filtered medium was subsequently mixed 
with ExoQuick-TC (System Biosciences), followed by cen-
trifugation at 3,000 g for 30 minutes at 4°C. The enriched 
exosome pellet was resuspended in a phosphate buffer and 
stored at -80°C for future use. The protein concentration 
of prepared exosomes was measured by NanoDrop Lite 
(Thermo Fisher Scientific).
luciferase assay
A Gluc assay was conducted as previously reported.38 Briefly, 
the conditioned medium was collected and centrifuged 
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Figure 1 strategy of exosome pseudotyping.
Notes: (A) Membrane topology of the fVsVg. The matured fVsVg is a single transmembrane protein without the sP. The large N-terminal ectodomain (black line) 
with a short stem region (green line) is situated at the outer surface of the plasma membrane or the luminal side of the endosome. Those sequences are followed by a 
transmembrane helix and a cytoplasmic tail. (B) Design of VsVg fusion constructs. From top to bottom, the fVsVg fused with either rFP (fVsVg-rFP) or gFP (fVsVg-gFP) 
at the c-terminal, the ectodomain was replaced by rFP (rFP-mVsVg), the fVsVg fused with Gaussia luciferase (gluc) at the c-terminal (fVsVg-gluc), and the ectodomain 
was replaced by gluc (gluc-mVsVg). (C) a proposed model illustrating how VsVg participates in exosomes in a mammalian cell. ectopic expression of VsVg occurs at 
the rough endoplasmic reticulum (er) via its sP guiding, and subsequently sP-cleaved VsVg is funneled to the plasma membrane and becomes concentrated in tetraspanin 
(CD63)-enriched microdomains, where the first inward budding begins to form endosomes. The second inward budding from the endosome forms exosomes that are stored 
in a MVB prior to release into extracellular space. (D) schematic illustration of the pseudotyped and protein-loaded exosome. Membrane topology of VsVg (black), loaded 
protein cargo gFP (green) or rFP (red), and exosome markers (cD63/cD81, blue) are indicated.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg; MVB, multiple-vesicle body; sP, signal peptide.
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at 1,500 g for 5 minutes. In a typical experiment, 20 µL 
of conditioned medium containing the modified exosomes 
was analyzed for Gluc activity using a Synergy HT multi-
mode microplate reader (BioTek Instruments, Winooski, 
VT, USA). Data are presented as relative light units for 
comparison.
exosome pull-down assay
An exosome pull-down assay was conducted using an 
Exo-Flow kit (System Biosciences). Briefly, 20 µL of 
streptavidin-coupled magnetic beads was mixed with 15 µL 
of biotin-labeled CD81 antibody for 2 hours at 4°C. The 
beads were then washed, and 50 µg of pseudotyped exo-
somes was incubated overnight with the antibody-captured 
beads. These exosome pull-down beads were then washed 
extensively and transferred to clear wells of a 96-well plate 
prior to imaging. Beads without CD81 antibodies were used 
as negative controls.
Nanoparticle-tracking analysis (NTa)
Exosomes isolated from transfected cells were subjected 
to NTA using an NS300 machine (Malvern Instruments, 
Malvern, UK). In a typical analysis, 1 mL of the diluted exo-
somes (~1:1,000 dilutions) was used for exosome visualiza-
tion by laser-light scattering, and three videos of 60 seconds 
each were recorded. Data analysis was performed by NTA 
software, and the results are presented graphically to show 
particle size and distribution.
exosome uptake assay
Recipient cells were seeded in a 96-well plate and incubated 
with exosomes as indicated in each experiment. Briefly, 
nonstem cells at 20%–30% confluence were loaded with 
5 µg exosome protein/well in serum-free UltraCulture 
medium. Cells were then imaged at 20× magnification using 
fluorescence microscopy (DMI3000B; Leica Microsystems, 
Wetzlar, Germany). For iPS cell lines, cells were cultured 
on a Matrigel-coated plate and loaded with exosomes in 
serum-free mTeRS1 medium. After an extensive wash, 
loaded iPS cells were imaged at 10× magnification using an 
Evos FL autofluorescence microscope. Microscopic imaging 
parameters (exposure time, contrast, and gain) were the same 
for all experiments.
Fluorescence-activated cell-sorting 
analysis
HEK293 or U87A cells were sorted and quantified using flow 
cytometry (Accuri C6; BD Biosciences, San Jose, CA, USA) 
following a 2-day transfection. Events (10,000–30,000) 
were recorded for each sample using an FL3A channel to 
detect the fluorescence of RFP. Fluorescence-activated 
cell-sorting data were analyzed with CFlow Plus software 
(BD Biosciences).
live cell microscopy
Images were typically taken on live cells using fluorescence 
microscopy. To show the intracellular localizations of the 
fluorescent fusion proteins, fluorescent and phase-contrast 
images were adjusted for brightness and contrast or over-
laid using Adobe Photoshop CS. Whenever for quantitative 
comparison, all imaging data were obtained using identical 
parameters (exposure time, contrast, and gain).
Results
experimental design and pseudotyping 
strategy
First, we developed a strategy to repurpose exosomes as 
vehicles for in vivo targeted delivery and imaging of protein-
based therapeutics and fluorescent probes. Key to the success 
of our pseudotyping approach was to control the topology of 
VSVG on the exosome membrane. We hypothesized that the 
preferred topology of VSVG on the exosome would be one 
where the VSVG protein is retained in the membrane by the 
interaction of its hydrophobic tail with the bilayer membrane. 
This anchoring strategy would position the ectodomain of 
fVSVG to the outer surface of the exosome for pseudotyping 
(Figure 1A and D). Moreover, by fusing targeting molecules 
to fVSVG, one could maximize interactions of the exosome 
with surface antigens on the plasma membrane of a target cell. 
Alternatively, by swapping the ectodomain with a cell-trophic 
peptide or a disease-targeting antibody, one could target the 
exosome to a specific tissue or tumor.39 This latter approach 
could be further refined for in vivo targeted therapy and 
imaging of tumors or diseased tissue by fusing an engineered 
antibody or a near-infrared fluorescent protein.
To test this new approach, we constructed several fusion 
proteins composed of fVSVG with fluorescent or luminescent 
reporters by way of domain swapping and protein tagging. 
To ensure these fusion proteins were properly anchored 
with the correct topography on exosomal membranes, the 
SP sequences and the transmembrane helix of fVSVG were 
left intact in all fusion proteins (Figure 1B). This strategy 
would limit the synthesis of VSVG to the surface of the 
rough ER, with the SP sequence guiding the insertion of the 
ectodomain into the ER lumen (Figure 1C). In a later section 
of the manuscript, we show this strategy correctly positions 
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the transmembrane helix of VSVG fusion proteins in the 
membrane of HEK293 cells, with the C-terminal tail project-
ing into the cytoplasm. Previous studies have shown that the 
SP sequence is removed and the remaining VSVG molecules 
concentrate in tetraspanin-enriched microdomains of the 
plasma membrane.40,41 Exosomes are believed to form these 
domains in two sequential inward-budding processes: the first 
generates an endosome, while the second leads to the forma-
tion of multiple-vesicle bodies that eventually release indi-
vidual exosomes into the extracellular space (Figure 1C).7
VSVG introduces functional fluorescent 
proteins to presecreted exosomes
Next, we examined if the proteins we appended to VSVG 
were functional and correctly positioned on the exosomal 
membrane. First, we generated two fusion proteins tagged 
with GFP or RFP at the C-terminus of VSVG. Cultured 
HEK293 cells were transfected with these constructs, and 
their intracellular localization expression was recorded for 
up to 7 days by fluorescence microscopy. Analysis of these 
image data shows accumulations of fluorescent proteins at 
plasma membranes of HEK293 cells within 2 days of the 
transfection (Figure 2A and E). The membrane localization 
of these fluorescent proteins was evident when comparing 
fluorescence signals with the phase contrast in merged images 
(Figure 2B and F). By day 3, the fluorescence signal of the 
fusion protein was found at other intracellular regions of 
the cell (Figure 2C and G). The punctate intracellular fluo-
rescence was consistent with that expected for endocytic 
structures (Figure 2D and H). We argue the intracellular 
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Figure 2 Fluorescent imaging of VsVg fusion proteins in heK293 cells.
Notes: cultured cells were transfected with either fVsVg-gFP/fVsVg-rFP alone or in combination with rab5a-gFP/cD63-gFP for indicated periods of time. cell images of 
fluorescence signal and phase contract of the same field were taken to show the expression and an earlier plasma membrane distribution of fVSVG-GFP on day 2 (A, green; 
B, overlay), and late-punctate intracellular localization on day 3 (C, green; D, overlay). similarly, the expression and subcellular localization of fVsVg are shown in red 
(E–H). Interestingly, following cotransfection of cells with fVsVg-rFP and rab5a-gFP (an endosome marker) for 3 days, images show the expression and cellular distribution 
of fVsVg (I, red), rab5a (J, green), or colocalization of both (K, yellow). alternatively, cotransfection with both fVsVg-rFP and cD63-gFP (an exosome marker) resulted 
in similar patterns of expression and cellular distribution for fVsVg (L, red), cD63 (M, green), and colocalization of both (N, yellow). arrows indicate endosome/exosome/
MVB structures. scale bar 20 µm.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; MVB, multiple-vesicle body; sP, signal peptide.
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puncta represent endosomes and are formed by the inward 
budding of the plasma membrane.
Next, we conducted imaging studies to verify the fluores-
cence of VSVG fusion expressed in HEK293 cells colocal-
ized to endocytic compartments by comparing distributions 
of VSVG fluorescence with validated fluorescent markers of 
the endosome. These studies, conducted in cells cotransfected 
with fVSVG-RFP (red) and an endosome marker, Rab5A-
GFP (green), showed considerable overlap of the two fluo-
rescent signals that was immediately apparent by the large 
number of yellow puncta in overlaid images (Figure 2I–K) 
and provide compelling evidence that fluorescent fVSVG 
fusion protein localizes to endosomes.
Next, we conducted studies to show fluorescent endo-
somal vesicles were components of the exosome biogenesis 
pathway. We cotransfected HEK293 cells with fVSVG-
RFP (red) and CD63-GFP (green), a validated marker of 
exosomes. High-resolution fluorescence imaging of cells 
transfected with these two constructs also revealed extensive 
overlap of the green and red fluorescence signals, which can 
be appreciated in merged images that highlight overlapping 
signals in yellow (Figure 2L–N). These results confirm the 
expectation that fVSVG participates in the biogenesis of the 
endocytic compartment as presecreted exosomes.
Together, the results of these imaging studies are consis-
tent with our hypothesis that fVSVG serves as a molecular 
scaffold that both integrates and correctly projects appended 
proteins, including RFP, in the exosomal membrane. The 
readily detectable fluorescence of RFP suggests that protein 
payloads on fVSVG are functional, and protein integration 
into the exosome membrane is highly efficient.
Identification of the minimal VSVG 
scaffold for exosome targeting
fVSVG is a single transmembrane glycoprotein that is char-
acterized by a spike that protrudes on the outer face of the 
viral particle. In the present study, fVSVGs are shown to 
integrate into exosome membranes, with the ectodomain pro-
jecting from the external face.42 The ectodomain of fVSVG 
recognizes specific proteins on the surface of recipient cells 
and facilitates attachment and internalization.42,43 We asked 
whether mVSVG, a construct that lacks the ectodomain, 
is sufficient to anchor the protein to the exosomal mem-
brane. In these studies, the ectodomain was replaced with 
RFP, although the fusion protein contained the N-terminal 
SP (54aa) and the C-terminal domain (70aa) (Figure 1B). 
We recorded images of the red fluorescence of RFP-mVSVG 
in transfected HEK293 cells. The red fluorescence localized 
to the same type of puncta we found for mVSVG fusion 
proteins that were identified as potentially endocytic com-
partments (Figure 3A, D, and G). Importantly, we found 
extensive overlap of the red and green fluorescence signals 
in cells cotransfected with RFP-mVSVG and each of the 
fluorescent fusion proteins fVSVG-GFP (Figure 3B and C), 
Rab5A-GFP (an endosome marker, Figure 3E and F), CD63-
GFP (an exosome marker, Figure 3H and I), and CD81-
GFP (Figure S1), strongly suggesting endosome/exosome 
participation. These data identify the SP domain and the 
C-terminus of VSVG as the “minimal” scaffold of VSVG 
for exosome targeting.
VsVg incorporation into exosomes via 
endogenous pathway
Next, we examined how VSVG is incorporated into exo-
somes in HEK293 cells by recording the kinetics of fVSVG 
and XPack exosome-tracer participation into exosomes. 
After their transfection in HEK293 cells, the fluorescence 
of RFP-fVSVG and XPack-GFP was recorded as a func-
tion of time in live cells. These imaging studies conformed 
with initial findings on the early appearance of RFP at the 
plasma membrane (Figure 4A, upper panel, days 1 and 2) and 
late participation of fVSVG-RFP in intracellular granules, 
tentatively assigned as exosomes (Figure 4A, upper panel, 
days 4 and 6). Analysis of the corresponding images of 
XPack-GFP showed a similar temporal pattern (Figure 4A, 
lower panel), which would suggest that fVSVG and XPack 
share a common pathway in exosome biogenesis. After 
cotransfection, analysis of fluorescence images of these 
two independent fluorescent tracers revealed extensive 
colocalization (Figure 4B), indicating they shared similar 
intracellular distribution in HEK293 cells. These findings 
support our hypothesis that VSVG is preferentially recruited 
into exosomes via the endocytic pathway.
To explore whether the incorporation of VSVG into 
exosomes is a general phenomenon, we transfected VSVG-
reporter proteins into three additional cell lines: U87, HEPG2, 
and L929. The distribution of fVSVG-RFP was recorded 
dynamically in each type of living cell using fluorescence 
microscopy. These studies showed the fVSVG fusion pro-
tein localizes to punctate structures in all three cell types 
and strongly suggests that fVSVG plays a common role 
in exosome biogenesis in a variety of human cell types 
(Figure S2A). Moreover, we found that the intracellular 
pattern of RFP-mVSVG was similar to fVSVG in the addi-
tional cell lines (Figure S2B). Together, our data show that 
fVSVG and mVSVG are capable of targeting and introducing 
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Figure 3 Validation of minimal VsVg (mVsVg) scaffold for exosome targeting.
Notes: HEK293 cells were cotransfected with RFP-mVSVG and fVSVG-GFP for 3 days. Cell images were taken by fluorescence microscopy to show the intracellular 
expression of mVsVg (A, red), fVsVg (B, green), and colocalization of both (C, yellow). alternatively, cells were cotransfected with rFP-mVsVg and endosome marker 
rab5a-gFP for 3 days. expression and subcellular distribution were shown for mVsVg (D, G; red), rab5a (E, green) and colocalization of both in overlay (F, yellow). similar 
results were obtained to show the expression and subcellular distribution of exosome marker cD63 (H) and its colocalization with mVsVg (I, yellow). arrows indicate 
endosome/exosome/MVB structures. scale bar 20 µm.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg; MVB, multiple-vesicle body; sP, signal peptide.
functional fusion proteins into exosomal membranes in 
human and murine cells.
characterization of pseudotyped 
exosomes released from transfected cells
Next, we asked if VSVG-pseudotyped exosomes were 
released from their producing cell to the extracellular 
space. First, we constructed two additional VSVG report-
ers: mVSVG and fVSVG fusions of the highly lumines-
cent luciferase from Gaussia princeps (Figure 5A). If the 
pseudotyped exosomes are released from transfected cells, 
high levels of luciferase activities could be expected from 
the conditioned medium. As predicted, we detected high 
levels of luciferase in conditioned medium: 1,734-fold 
and 250-fold higher for Gluc-mVSVG and fVSVG-Gluc, 
respectively, compared to those of the untransfected controls 
(Figure 5B). The difference in the activity of the transfected 
luciferase fusion proteins for these two reporters could arise 
from the limited availability of the coelenterazine substrate, 
since the Gluc-mVSVG is on the outer surface of the exosome, 
and hence it is more accessible to the substrate. Nevertheless, 
these results suggest fVSVG/mVSVG carry their appended 
luciferase onto exosomes in an active form, and in both cases 
the exosomes are released into the extracellular space.
Next, we provided further confirmation that the VSVG-
pseudotyped vesicles produced by HEK293 cells are true 
exosomes. In these studies, exosomes were pulled down 
from suspensions using an anti-CD81 (an exosome marker) 
antibody. Since the immunoprecipitated complex in the 
pull-downs emitted strong GFP fluorescence, we are quite 
certain they contained fVSVG-GFP, while the presence of 
CD81 confirmed they were exosomes (Figure 5C).
Next, we asked if the differential pseudotyping of 
exosomes affected their physical properties. In particular, 
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Figure 4 Time course of VsVg fusion incorporation into exosomes.
Notes: heK293 cells were transfected with fVsVg-rFP or XPack-gFP alone (an exosome tracer) for indicated periods of time. The incorporation of fVsVg into exosomes 
was monitored and compared with that of XPack. live cell images were taken at days 1, 2, 4, and 6; representative images are shown to illustrate the expression of fVsVg 
(A, top panel) and XPack (A, bottom panel) at early membrane appearance (days 1 and 2), and final incorporation in exosomes (days 4 and 6). (B) In a separate set of 
experiments, cells were cotransfected with fVsVg-rFP and XPack-gFP for 3 days. The expression of fVsVg (red), XPack (green), and colocalization of both (yellow in 
overlay) are shown. arrows indicate membrane locations and endosome/exosome/MVB structures. scale bar 20 µm.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; mVsVg, minimal VsVg; fVsVg, full-length VsVg; MVB, multiple-vesicle body.
NTA of a suspension of exosomes was assessed using the 
NS300. The average diameters of pseudotyped exosomes 
integrated with fVSVG-RFP and RFP-mVSVG were similar 
(Figure 5D and E) and did not differ significantly from the 
average size determined for CD63-GFP, which acted as a 
control particle for these studies (Figure 5F and G).
Pseudotyping increases exosome uptake 
by recipient cells
We next studied the uptake of VSVG-pseudotyped exosomes 
by recipient cells. A key question is whether the ectodomain 
of VSVG may modulate the binding and uptake of exosomes. 
In this set of studies, we compared the binding and uptake 
of exosomes pseudotyped with fVSVG versus mVSVG. 
The delivery of the two classes of engineered exosomes to 
target cells was determined by imaging the distribution of 
intracellular red fluorescence in HEK293, HEPG2, U87, 
and L929 cells after incubation with the RFP-labeled exo-
somes (5 µg/well). Cells incubated with purified exosomes 
for 48 hours were imaged using fluorescence microscopy. 
Approximately 95% of HEPG2, U87, and HEK293 cells 
showed strong perinuclear fluorescence due to the uptake 
of RFP-fVSVG-loaded exosomes (Figure 6A, C, E, and G). 
On the other hand, only weak red fluorescence was recorded 
after incubating the same cell types with mVSVG-modified 
exosomes (Figure 6B, D, F, and H). These results led to two 
important conclusions: first, exosome delivery to recipient 
cells is enhanced by fVSVG pseudotyping, and second the 
ectodomain of fVSVG plays an important role in the binding 
and subsequent uptake of exosomes by recipient cells.
Encouraged by the observations just described, we 
examined exosome uptake in more complex cell types, 
including human iPS cells, which are notoriously difficult 
to transfect using standard transfection protocols. Fluores-
cence images of iPS cells incubated with a fixed number 
of fVSVG-RFP-pseudotyped exosomes for 24 hours 
showed strong intracellular fluorescence in 50%–60% of 
iPSC11 and 40%–50% of iPSC15 cells (Figure 6I and K). 
Notably, the highest levels of exosome uptake were found 
in cells at the periphery of stem cell colonies, suggesting 
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Figure 5 secretion and characterization of pseudotyped exosomes.
Notes: (A) Configuration of Gaussia luciferase reporters used for monitoring exosome secretion. (B) Gaussia luciferase activity was assayed using conditioned media from 
heK293 cell culture on day 2 posttransfection, with mock transfection as negative controls. Data presented as relative light units from three experiments (mean ± standard 
deviation, n=3). (C) Immunological pull-down of pseudotyped exosomes using CD81-specific antibody (Ab)-coated beads. Both images of green fluorescence and phase 
contrast are displayed to show gFP-positive anti-cD81 antibody-precipitated exosomes. Non-ab-coated beads were included as controls. arrows indicate exosome-
positive beads. (D–F) Nanoparticle-tracking analysis profiles off VSVG, mVSVG, or CD63 pseudotyped exosomes isolated from HEK293 cells at 3 days posttransfection, 
showing average sizes of respective exosomes. (G) There was no difference in average exosome size between pseudotyped fVSVG-RFP/RFP-mVSVG and modified CD63 
(an endogenous exosome marker).
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; mVsVg, minimal VsVg; fVsVg, full-length VsVg; sP, signal peptide.
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Figure 6 exosome uptake in mammalian cells.
Notes: Uptake of pseudotyped exosomes in various cell lines (hePg2, U97, heK293, l929, iPsc11, and iPsc15) was compared between fVsVg and mVsVg. cultured 
cells were treated with either fVsVg-rFP or rFP-mVsVg in a 96-well plate. enhanced uptake of fVsVg was evident (A–C and G–K) compared to mVsVg (D–F and 
H–L). Following exosome incubation for 48 hours, images were taken with fluorescent microscopy at 20× magnification for HEPG2, U97, HEK293, and L929 cells (scale 
bar 20 µm). For iPsc11 and iPsc15 cells, images were taken after exosome incubation for 24 hours at 10× magnification (scale bar 10 µm). arrows point to internalized 
rFP-labeled exosomes.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg.
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the metabolic status of highly proliferating cells may 
influence exosome uptake. As expected, mVSVG-loaded 
exosomes were found to be taken up at low levels in iPS 
cells, confirming our earlier finding that the pseudotyping 
(ectodomain) domain is critical for effective attachment 
and internalization by recipient cells.
Next, we used fluorescence-activated cell-sorting analysis 
to quantify further the uptake of differentially pseudotyped 
exosomes by human cells. In these studies, we compared the 
uptake of fVSVG-RFP- versus RFP-mVSVG-pseudotyped 
exosomes in HEK293 cells after a 48-hour incubation. 
The plots in Figure 7A and B show the population of 
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Figure 7 Quantification of exosome uptake in HEK293 cells by flow cytometry.
Notes: Recipient cells were loaded with either fVSVG-RFP or RFP-mVSVG pseudotyped exosomes for 48 hours, then washed and subjected to fluorescence-activated 
cell-sorting analysis. Right shifts in fluorescence signals for both fVSVG (C) and mVsVg (B) exosomes are shown in comparison with the negative control (A) in panel (D), 
indicating an enhancement (~9.7-fold) in exosome uptake by pseudotyping in heK293 cells.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg.
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cells emitting RFP fluorescence shifted slightly to higher 
numbers for exosome types A and B compared to the control 
(Figure 7C). However, after subtracting the background fluo-
rescence signal measured from the negative control group, 
we measured a ~9.7-fold increase in exosome uptake for 
fVSVG- versus mVSVG-modified exosomes (Figure 7D). 
Similar results were obtained for exosome uptake in U87 cells 
(Figure S3A–C), while a more robust increase of 11.5-fold 
was recorded by pseudotyping with fVSVG versus mVSVG 
(Figure S3D). Together, our results demonstrated that the 
uptake of exosomes by diverse cell types can be enhanced 
by producing VSVG-pseudotyped exosomes bearing the 
ectodomain in this process.
Discussion
Protein therapeutics are finding increasing popularity in 
the treatment of health disorders, and they represent the 
fastest-growing class of FDA-approved biologics.1,2 Most 
protein therapeutics, however, are directed toward extra-
cellular targets, as they are difficult to transport across the 
plasma membrane of mammalian cells. In this study, we 
have described a new pseudotyping approach to engineer 
exosomes as vehicles for the intracellular delivery of protein 
cargo, imparted by enhancing their intrinsic ability to deliver 
bioactive cargo to recipient cells.7,44
Our studies build on well-established principles underly-
ing VSVG pseudotyping, which has been used to produce 
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recombinant viruses (murine retroviruses and HIV1) and to 
enhance the efficiency of gene delivery.31,32 In these early 
studies, VSVG and viral structure proteins were coexpressed 
and incorporated into the viral envelope to form infectious 
recombinant viruses, rather than exosomes. Maguire et al45 
used VSVG to pseudotype extracellular vesicles and found 
that adeno-associated virus coupled with these pseudotyped 
vesicles gained enhanced ability of gene delivery, implicating 
extracellular vesicles with viral infection. In later studies, 
Marsac et al46 and Kuate et al47 used VSVG to boost antibody 
production against viral peptides, including the severe acute 
respiratory syndrome-associated coronavirus (SARS-CV) 
S protein and an HIV-Gag epitope. In both cases, both VSVG 
and a viral protein (SARS-CV-S protein or HIV-Gag) were 
included as components of the exosome-based vaccination 
material. Notably, Mangeot et al6 were able to use VSVG 
alone to produce VSVG-induced nanovesicles, termed 
“gesicles”, for protein transfer into human cells, avoiding 
viral delivery totally. Although those studies pointed to the 
possibility of a convergent mechanism via vesicle pseudo-
typing, the exact molecular mechanisms and final destina-
tion of VSVG in living mammalian cells remain elusive. 
Importantly, whether the VSVG molecule has an intrinsic 
ability to target exosomes and thus can be particularly used 
for exosome engineering remains to be tested. 
In our studies, we introduced VSVG fusion proteins into 
exosome membranes in an effort to repurpose exosomes as 
living vehicles for targeted delivery of a protein cargo to 
recipient cells. Importantly, this repurposing did not require 
any additional viral components. This approach led to the 
successful incorporation of protein payloads, including GFP, 
RFP, and luciferase, in exosomes. VSVG-modified exosomes 
were shown to form efficiently in host cells and were secreted 
to the extracellular space with the same physical properties 
as natural exosomes. Pseudotyping resulted in a dramatic 
increase in exosome uptake by a variety of mammalian cell 
types, including human iPS cells.
Pseudotyping of exosomes offers several key advantages 
for the intracellular delivery of protein therapeutics compared 
to liposomes and nanoscale polymers.48,49 First, exosomes are 
cell-derived nanoparticles with a diameter of 30–200 nm that 
are recognized as “self” by the host and present a repertoire 
of intrinsic surface proteins that allow them to gain access 
to tissues and tumor microenvironments and to circulate in 
the host for longer periods, which increases their chance to 
deliver their therapeutic cargo to deep-seated cells in solid 
tumors.50 Second, exosomes are capable of transporting spe-
cific proteins on their surfaces or within their internal cavity.51,52 
This feature was exploited in this study to load exosomes 
with a variety of reporter proteins, including GFP, RFP, and 
luciferase. This strategy can be further developed to deliver 
exosomes to defined cell types simply by appending VSVG 
with an enzyme that could form the basis of a replacement 
therapy for a hereditary disease, or cell-recognizing peptides 
for targeting, or engineered therapeutic antibodies that target 
specific suppressors of cytotoxic T cells for cancer therapy.53 
Third, we have demonstrated that exosomes pseudotyped with 
VSVG are internalized by a diverse collection of human and 
murine cells, including two human iPS cell lines. This targeting 
and the subsequent internalization of exosomes by recipient 
cells require the ectodomain. Fourth, the role of the VSVG 
ectodomain for protein loading and delivery is multifaceted. 
The native VSVG ectodomain is dispensable for protein load-
ing, and thus deletion of the ectodomain can make room for 
other polypeptide loading. For example, RFP can replace the 
ectodomain, and chimeric protein can be loaded onto exo-
somes. Because the ectodomain serves as an important docking 
molecule for exosome loading, it can be potentially replaced 
with other cell-tropic peptides; therefore, this strategy can be 
used for engineering targeted exosomes for delivery. 
Collectively, our studies demonstrate the feasibility of 
using VSVG pseudotyping to engineer exosomes as bio-
compatible vehicles with enhanced molecular functions that 
increase the targeting and delivery of protein therapeutics or 
modulators of gene expression to specific cells in a disease 
tissue, or serve to deliver probes for in vivo imaging of 
tumors.
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Supplementary materials
supplementary sequences
Wild-type full-length vesicular stomatitis virus glycoprotein 
VSVG (fVSVG) coding sequence and protein sequences, as 
well as fusion protein configuration, sequences, and domain 
annotation follow.
coding sequences of wild-type fVsVg
atgttcatgccttcttctctttcctacagctcctgggcaacgtgctggttgttgt 
gctgtctcatcattttggcaaagaattcctcgacggatccctcgaggaattct 
gacactatgaagtgccttttgtacttagcctttttattcattggggtgaattg 
caagttcaccatagtttttccacacaaccaaaaaggaaactggaaaaatgttcct 
tctaattaccattattgcccgtcaagctcagatttaaattggcataatgacttaatag 
gcacagccttacaagtcaaaatgcccaagagtcacaaggctattcaagcagacg 
gttggatgtgtcatgcttccaaatgggtcactacttgtgatttccgctggtatg 
gaccgaagtatataacacattccatccgatccttcactccatctgtagaacaatg 
caaggaaagcattgaacaaacgaaacaaggaacttggctgaatccaggcttc 
cctcctcaaagttgtggatatgcaactgtgacggatgccgaagcagtgattgtccag 
gtgactcctcaccatgtgctggttgatgaatacacaggagaatgggttgattca 
cagttcatcaacggaaaatgcagcaattacatatgccccactgtccataactcta 
caacctggcattctgactataaggtcaaagggctatgtgattctaacctcatttccatg 
gacatcaccttcttctcagaggacggagagctatcatccctgggaaaggagggca 
cagggttcagaagtaactactttgcttatgaaactggaggcaaggcctgcaaaat 
gcaatactgcaagcattggggagtcagactcccatcaggtgtctggttcgagatg 
gctgataaggatctctttgctgcagccagattccctgaatgcccagaagggt 
caagtatctctgctccatctcagacctcagtggatgtaagtctaattcaggacgt 
tgagaggatcttggattattccctctgccaagaaacctggagcaaaatcagagcg 
ggtcttccaatctctccagtggatctcagctatcttgctcctaaaaacccaggaac 
cggtcctgctttcaccataatcaatggtaccctaaaatactttgagaccagatacat 
cagagtcgatattgctgctccaatcctctcaagaatggtcggaatgatcagtggaac 
taccacagaaagggaactgtgggatgactgggcaccatatgaagacgtggaaat 
tggacccaatggagttctgaggaccagttcaggatataagtttcctttatacatgat 
tggacatggtatgttggactccgatcttcatcttagctcaaaggctcaggtgttcgaa 
catcctcacattcaagacgctgcttcgcaacttcctgatgatgagagtttatttttt 
ggtgatactgggctatccaaaaatccaatcgagcttgtagaaggttggttcagtagt 
tggaaaagctctattgcctcttttttctttatcatagggttaatcattggactattcttggt 
tctccgagttggtatccatctttgcattaaattaaagcacaccaagaaaagaca 
gatttatacagacatagagatgaaccgacttggaaagtaa
Protein sequences of wild-type fVsVg (549aa)
MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRN 
SDTMKCLLYLAFLFIGVNCKFTIVFPHNQKGNW 
KNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSH 
KAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRS 
FTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVT 
DAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCS 
NYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFF 
SEDGELSSLGKEGTGFRSNYFAYETGGKACKMQY 
CKHWGVRLPSGVWFEMADKDLFAAARFPECPEGS 
???????
??????????
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?????????
?
???
????????
?
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???????
?
Figure S1 colocalization of mVsVg with exosome marker cD81 in heK293 cells.
Notes: cultured cells were cotransfected with rFP-mVsVg and exosome 
marker CD81-GFP for 3 days. Cell images of the same field were taken to 
show the expression and subcellular localization of mVsVg (A, red), cD81 
(B, green), and colocalization of both (C, yellow). arrows indicate endosome/
exosome/MVB structures. scale bar 20 µm.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein;  mVsVg, minimal 
VsVg; MVB, multiple-vesicle body; sP, signal peptide.
SISAPSQTSVDVSLIQDVERILDYSLCQETWSKI 
RAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE 
TRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPY 
EDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL 
HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKN 
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Figure S2 Intracellular localization of VsVgs in multiple mammalian cell lines.
Notes: Cultured cells were transfected with either fVSVG-RFP or RFP-mVSVG for 3 days in U87, HEPG2, and L292 lines. Images of fluorescence signal and phase contract of 
the same field were taken to show the expression and subcellular localization of fVSVG (A) or mVsVg (B). arrows and overlay indicate endosome/exosome/MVB structures 
inside cells. scale bar 20 µm.
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg; MVB, multiple-vesicle body; sP, signal peptide.
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PIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHL 
CIKLKHTKKRQIYTDIEMNRLGK
Notes: Signal peptide; ectodomain; stem; transmembrane 
domain; cytoplasmic domain.
Protein sequences of fVsVg-gFP
MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRN 
SDTMKCLLYLAFLFIGVNCKFTIVFPHNQKGNW 
KNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSH 
KAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRS 
FTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVT 
DAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCS 
NYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFF 
SEDGELSSLGKEGTGFRSNYFAYETGGKACKMQY 
CKHWGVRLPSGVWFEMADKDLFAAARFPECPEGS 
SISAPSQTSVDVSLIQDVERILDYSLCQETWSKI 
RAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE 
TRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPY 
EDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL 
HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGL 
SKNPIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGI 
HLCIKLKHTKKRQIYTDIEMNRLGKESDESGLPA 
MEIECRITGTLNGVEFELVGGGEGTPKQGRMTNKM 
KSTKGALTFSPYLLSHVMGYGFYHFGTYPSGYEN 
PFLHAINNGGYTNTRIEKYEDGGVLHVSFSYRYEA 
GRVIGDFKVVGTGFPEDSVIFTDKIIRSNATVEHLHP 
MGDNVLVGSFARTFSLRDGGYYSFVVDSHMHFK 
SAIHPSILQNGGPMFAFRRVEELHSNTELGIVEY 
QHAFKTPIAFARSRAQSSNSAVDGTAGPGSTGSR
Notes: Signal peptide; ectodomain; stem; transmembrane 
domain; cytoplasmic domain; GFP.
Protein sequences of fVsVg-rFP
MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRN 
SDTMKCLLYLAFLFIGVNCKFTIVFPHNQKGNW 
KNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSH 
KAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRS 
FTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVT 
DAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCS 
NYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFF 
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exosome pseudotyping for enhanced protein delivery
Figure S3 Quantification of exosome uptake in U87 cells by flow cytometry.
Notes: cells at ~30% confluence were loaded with pseudotyped exosomes in a six-well plate. After 48 hours of incubation, cells were washed and subjected to fluorescence-
activated cell-sorting analysis. Right shifts in fluorescence signals for both fVSVG-RFP (C) and rFP-mVsVg (B) exosomes are shown in comparison with the negative control (A), 
indicating an enhancement (~11.5-fold) in exosome uptake by pseudotyping in U87 recipient cells (D).
Abbreviations: VsVg, vesicular stomatitis virus glycoprotein; fVsVg, full-length VsVg; mVsVg, minimal VsVg.
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SEDGELSSLGKEGTGFRSNYFAYETGGKACKMQY 
CKHWGVRLPSGVWFEMADKDLFAAARFPECPEGS 
SISAPSQTSVDVSLIQDVERILDYSLCQETWSKI 
RAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE 
TRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPY 
EDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL 
HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKN 
PIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHL 
CIKLKHTKKRQIYTDIEMNRLGKLTMASSEDVIKEF 
MRFKVKMEGSVNGHEFEIEGEGEGRPYEGTQTAK 
LKVTKGGPLPFSWDILSPQFQYGSKAYVKHPAD 
IPDYLKLSFPEGFKWERFMNFEDGGVVTVTQD 
STLQDGEFIYKVKLRGTNFPSDGPVMQKKTMGWEA 
STERMYPEDGALKGEIKMRLKLKDGGHYDAEVKT 
TYKAKKQVQLPGAYMTDIKLDIISHNGDYTIVEQY 
ERAEGRHSTGAGSIIRSI
Notes: Signal peptide; ectodomain; stem; transmembrane 
domain; cytoplasmic domain; RFP.
Protein sequences of rFP-mVsVg
M F M P S S L S Y S S W A T C W L L C C L I I L A K N S S T 
DPSRNSDTMKCLLYLAFLFIGVNCKFTIVFPHNG 
K L T M A S S E D V I K E F M R F K V K M E G S V N G H E 
FEIEGEGEGRPYEGTQTAKLKVTKGGPLPFSWDIL 
SPQFQYGSKAYVKHPADIPDYLKLSFPEGFKWERF 
MNFEDGGVVTVTQDSTLQDGEFIYKVKLRGTNFPS 
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DGPVMQKKTMGWEASTERMYPEDGALKGEIKMR 
LKLKDGGHYDAEVKTTYKAKKQVQLPGAYMTDIKL 
DIISHNGDYTIVEQYERAEGRHSTGAGSIIRSIGDTGL 
SKNPIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGI 
HLCIKLKHTKKRQIYTDIEMNRLGK
Notes: Signal peptide; ectodomain; RFP; stem; transmem-
brane domain; cytoplasmic domain.
Protein sequences of fVsVg–Gaussia luciferase
MFMPSSLSYSSWATCWLLCCLIILAKNSSTDPSRN 
SDTMKCLLYLAFLFIGVNCKFTIVFPHNQKGNW 
KNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPKSH 
KAIQADGWMCHASKWVTTCDFRWYGPKYITH 
SIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCG 
YATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQF 
INGKCSNYICPTVHNSTTWHSDYKVKGLCDSN 
LISMDITFFSEDGELSSLGKEGTGFRSNYFAYETG 
GKACKMQYCKHWGVRLPSGVWFEMADKDL 
FAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYS 
LCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTI 
INGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEREL 
WDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHG 
MLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFF 
GDTGLSKNPIELVEGWFSSWKSSIASFFFIIGLIIGL 
FLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLG 
KNEAKPTENNEDFNIVAVASNFATTDLDADRGKLPG 
KKLPLEVLKEMEANARKAGCTRGCLICLSHIKCTPK 
MKKFIPGRCHTYEGDKESAQGGIGEAIVDIPEIPGFK 
DLEPMEQFIAQVDLCVDCTTGCLKGLANVQ 
CSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD 
HHHHHH
Notes: Signal peptide; ectodomain; stem; transmembrane 
domain; cytoplasmic domain; Gaussia luciferase.
Protein sequences of Gaussia luciferase–mVsVg
M F M P S S L S Y S S W A T C W L L C C L I I L A K N S S T 
DPSRNSDTMKCLLYLAFLFIGVNCKFTIVFPH 
NEAKPTENNEDFNIVAVASNFATTDLDADRGKLPG 
KKLPLEVLKEMEANARKAGCTRGCLICLSHIKCTP 
KMKKFIPGRCHTYEGDKESAQGGIGEAIVDIPEIPG 
FKDLEPMEQFIAQVDLCVDCTTGCLKGLANVQCS 
DLLKKWLPQRCATFASKIQGQVDKIKGAGGDHHHH 
HHGDTGLSKNPIELVEGWFSSWKSSIASFFFIIGLIIGL 
FLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK
Notes: Signal peptide; ectodomain; Gaussia luciferase; stem; 
transmembrane domain; cytoplasmic domain.
